Trial resultsQ3 2026a window, not a day
HERIZON-GEA-01 second interim OS analysis (doublet) topline
Jazz reported results from its Phase 3 study of Ziihera (zanidatamab-hrii) for First-line HER2+ gastroesophageal adenocarcinoma in Q3 2026 (Jul–Sep). The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsClinical trial results · also called: readout / topline data
- Company
- Jazz Pharmaceuticals plc JAZZ
- Drug
- Ziihera (zanidatamab-hrii)
- For
- First-line HER2+ gastroesophageal adenocarcinoma
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Q3 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- Q2 2026 results (Aug 3, 2026): top-line results from the second interim overall survival analysis for the doublet regimen expected in 3Q26.
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- JAZZ headlines on this site
Jazz Pharmaceuticals plc
1 upcoming · 7 past catalysts
More from JAZZ
Jazz expects to report results from its Phase 3 study of Modeyso (dordaviprone) for Recurrent H3 K27M-mutant diffuse glioma in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Modeyso ACTION Phase 3 interim OS analysis · Clinical trial results (readout / topline data)
- Drug
- Modeyso (dordaviprone)
- For
- Recurrent H3 K27M-mutant diffuse glioma
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Q2 2026 results: company anticipates the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, supporting potential full approval.
- Checked
- Checked by a person when it was added
- Verify it
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- JAZZ headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page